SOLANA BEACH, Calif., Dec. 18, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced that Gus Bassani, Pharm. D., Vice President of Consulting, R&D and Formulations with the Professional Compounding Centers of America, Inc. (PCCA), will join its board of directors.
Imprimis Pharmaceuticals is dedicated to improving patient health and quality of life by leveraging a patented topical drug delivery platform that enables highly targeted site specific treatment. Its lead drug candidate, Impracor, utilizes the company's innovative Accudel cream formulation to deliver ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), to target underlying tissue where Impracor exerts its localized anti-inflammatory effect.
Bassani has been with PCCA since September 2002. Prior to that, he was a formulation pharmacist in the product development lab of a veterinary pharmaceutical company. He has worked in multiple pharmacy practice settings, located in Alaska, Iowa and Kansas, and has taught extemporaneous compounding principles to pharmacy students in Drake University's Pharmaceutics Laboratory course.
Compounding pharmacists work to solve problems for specific patients by devising alternative drug formulations and delivery platforms, an area where Bassani has extensive experience interacting with thousands of pharmacists around the world.
"We are very pleased to welcome Gus Bassani to the Imprimis team," said Mark L. Baum, Imprimis CEO. "He will provide invaluable assistance and insight as we bring our lead drug to market, and explore potential applications and markets for our patented drug delivery platform."
"I'm very excited to be part of the Imprimis board, and in a position to help guide drug development and future projects," Bassani said. "I believe my experience in pharmaceutical compounding, drug formulation and research and development will serve as an asset as Imprimis moves forward."
In addition to his role with PCCA, Bassani sits on the United States Pharmacopeia Council of Experts, a body that writes standards for the pharmaceutical industry. His term on the council runs through 2015.
Bassani will be the sixth member of the Imprimis board of directors. The board also includes Mark L. Baum, Robert Kammer, Jeff Abrams, Paul Finnegan and Stephen G. Austin.
About Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. For more information, visit http://imprimispharma.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contact: Mark L. Baum
Imprimis Pharmaceuticals, Inc.
SOURCE Imprimis Pharmaceuticals, Inc.